Eurofins Scientific SE
ERFSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.33 | -5.72 | 0.39 | -1.28 |
| FCF Yield | 2.36% | 4.95% | 3.12% | 3.01% |
| EV / EBITDA | 19.94 | 20.62 | 17.12 | 25.26 |
| Quality | ||||
| ROIC | 5.94% | 0.22% | 5.59% | 8.00% |
| Gross Margin | 22.43% | 111.98% | 22.13% | 33.52% |
| Cash Conversion Ratio | 2.13 | 2.36 | 2.40 | 3.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.68% | 10.42% | 14.04% | 16.60% |
| Free Cash Flow Growth | -36.15% | 52.72% | -8.00% | 494.41% |
| Safety | ||||
| Net Debt / EBITDA | 4.11 | 4.88 | 3.80 | 4.88 |
| Interest Coverage | 10.66 | 0.41 | 8.32 | 13.07 |
| Efficiency | ||||
| Inventory Turnover | 19.20 | -2.98 | 18.69 | 18.57 |
| Cash Conversion Cycle | 20.06 | 145.56 | 22.20 | 30.61 |